← Leaderboards
Elton Jeffrey North
Creighton University
$1,171,323
Attributed
$1,171,323
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $618.7K · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$1,171,323 · 2
By mechanism
P20$807,573 · 1
R15$363,750 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroMouse ModelDrug KineticsInfectionLung DiseasesMethodologyAbsorptionDesignFda ApprovedIndolesLeadLead CandidateAmikacinAntibioticsAntimicrobialAntimycobacterial AgentsCytotoxicityBiologicalCystic Fibrosis PatientsEnsureCellsGenus MycobacteriumComplexMycobacterial
Grant awards (5)
Development of Novel Therapeutics for Treatment of Mycobacterial Infections$72,609
P20 · FY2024 · GM · contact PI
Development of Novel Therapeutics for Treatment of Mycobacterial Infections$227,770
P20 · FY2023 · GM · contact PI
Development of Novel Therapeutics for Treatment of Mycobacterial Infections$252,199
P20 · FY2022 · GM · contact PI
Discovery of Novel Nontuberculous Inhibitors$363,750
R15 · FY2021 · AI · contact PI
Development of Novel Therapeutics for Treatment of Mycobacterial Infections$254,995
P20 · FY2021 · GM · contact PI